Ping An Biomedical Co., Ltd. (PASW) Key Metrics
PASW key metrics, FY2023–FY2025
Fiscal year ended September 30, 2025 · Chinese yuanPASW returns How much profit the business earns on the capital it uses.
PASW financial health Debt, liquidity and how easily interest is covered.
PASW efficiency & capital use Working capital cycle and where the cash goes.
PASW returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PASW debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PASW cash returned to shareholders
PASW key metrics in Chinese yuan
FY2023–FY2025| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Returns & profitability | |||
| Return on equity (ROE) | −67.4% | — | — |
| Return on invested capital (ROIC) | −40.0% | −0.0% | 0.8% |
| Return on assets (ROA) | −20.5% | −1.9% | −1.2% |
| Return on tangible assets | −18.8% | −2.3% | −1.2% |
| Free cash flow margin | −18.8% | 16.7% | −7.4% |
| Financial health | |||
| Total debt | CN¥10.5M | CN¥10.8M | CN¥43.0M |
| Cash & short-term investments | CN¥1.2M | CN¥130,923 | CN¥591,874 |
| Net debt | CN¥9.3M | CN¥10.7M | CN¥42.4M |
| Debt / equity | 0.23 | — | — |
| Debt / assets | 0.15 | 0.19 | 0.54 |
| Net debt / EBITDA | — | 325.68 | 23.35 |
| Current ratio | 2.76 | 0.84 | 0.89 |
| Quick ratio | 2.74 | 0.84 | 0.86 |
| Interest coverage | -47.9 | -0.0 | 0.4 |
| Working capital | CN¥40.6M | −CN¥10.3M | −CN¥9.1M |
| Invested capital | CN¥54.5M | CN¥3.5M | CN¥36.5M |
| Tangible asset value | CN¥45.2M | −CN¥7.2M | −CN¥5.9M |
| Net current asset value | CN¥40.5M | −CN¥10.7M | −CN¥9.1M |
| Capital allocation | |||
| Dividends paid | CN¥0 | CN¥322,412 | CN¥9.6M |
| Dividends + buybacks / free cash flow | — | 2.2% | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% |
| Capex / operating cash flow | — | 0.0% | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 |
| SG&A / revenue | 18.5% | 5.5% | 3.9% |
| Efficiency | |||
| Days sales outstanding | 308.7 | 211.6 | 269.9 |
| Days of inventory on hand | 3.1 | 7.4 | 14.9 |
| Days payables outstanding | 134.5 | 54.0 | 43.2 |
| Cash conversion cycle (days) | 177.3 | 164.9 | 241.6 |
| Receivables turnover | 1.18 | 1.73 | 1.35 |
| Payables turnover | 2.71 | 6.76 | 8.45 |
| Inventory turnover | 116.65 | 49.58 | 24.56 |
| Asset turnover | 0.55 | 1.28 | 1.03 |
| Average receivables | CN¥28.9M | CN¥50.8M | CN¥61.1M |
| Average payables | CN¥12.2M | CN¥12.2M | CN¥9.3M |
| Average inventory | CN¥284,600 | CN¥1.7M | CN¥3.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from PASW's annual financial statements (latest annual report filed September 30, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Chinese yuan; data from EODHD. Averages use the opening and closing balance of each year.
PASW valuation and financial ratios
Ping An Biomedical earned a return on equity of −67.4% and a return on invested capital of −40.0% in fiscal 2025. It ended the year with CN¥10.5 million of debt and CN¥1.2 million in cash and short-term investments, net debt of CN¥9.3 million.
See the PASW income statement, the PASW chart for price history, or the PASW stock overview for the latest quote and news.
PASW key metrics FAQ
What is Ping An Biomedical's return on equity?
Ping An Biomedical's return on equity (ROE) was −67.4% in fiscal 2025: net income of -CN¥12.8 million on average shareholders' equity of CN¥19.0 million.
What is Ping An Biomedical's ROIC?
Ping An Biomedical's return on invested capital was −40.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Ping An Biomedical have?
Ping An Biomedical had total debt of CN¥10.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.23.
Does Ping An Biomedical pay a dividend?
Ping An Biomedical did not pay a dividend in fiscal 2025.
What is Ping An Biomedical's current ratio?
Ping An Biomedical's current ratio was 2.76 at the end of fiscal 2025: current assets were 2.76 times current liabilities.